Results 71 to 80 of about 21,287 (236)

Biomarkers of Kidney Disease Progression in ADPKD

open access: yesKidney International Reports
Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic kidney disorder and the fourth leading cause of kidney failure (KF) in adults.
Ahmad Ghanem   +10 more
semanticscholar   +1 more source

A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.

open access: yesJournal of the American Society of Nephrology, 2018
In the past, the treatment of autosomal dominant polycystic kidney disease (ADPKD) has been limited to the management of its symptoms and complications. Recently, the US Food and Drug Administration (FDA) approved tolvaptan as the first drug treatment to
F. Chebib   +10 more
semanticscholar   +1 more source

A high-throughput screening platform for Polycystic Kidney Disease (PKD) drug repurposing utilizing murine and human ADPKD cells

open access: yesScientific Reports, 2020
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited monogenic disorders, characterized by a progressive decline in kidney function due in part to the formation of fluid-filled cysts.
Rosita R. Asawa   +10 more
semanticscholar   +1 more source

Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.

open access: yesAmerican Society of Nephrology. Clinical Journal, 2020
BACKGROUND AND OBJECTIVES Nephrolithiasis is a common health problem in autosomal dominant polycystic kidney disease (ADPKD) and significantly contributes to patient morbidity.
M. Bargagli   +7 more
semanticscholar   +1 more source

Development of atypical genes in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

open access: yes, 2023
reservedIntroduzione: La malattia del rene policistico (PKD) è una malattia genetica caratterizzata principalmente dalla formazione di cisti a livello del parenchima renale e progressiva perdita della funzione renale determinando insufficienza renale ...
CRACCO, FRANCESCA
core  

Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment [PDF]

open access: yes, 2018
Rashid A Barnawi,1 Rahaf Z Attar,1 Sultan S Alfaer,1 Osama Y Safdar2 1Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; 2Pediatric Nephrology Center of Excellence, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia ...
Safdar OY   +7 more
core   +1 more source

Characteristics of Patients with End-Stage Kidney Disease in ADPKD

open access: yesKidney International Reports, 2020
Introduction Cystic expansion damaging the parenchyma is thought to lead to end-stage kidney disease (ESKD) in autosomal dominant polycystic kidney disease (ADPKD).
Shehbaz Shukoor   +14 more
semanticscholar   +1 more source

A secondary analysis of concurrent use of metformin and tolvaptan in ADPKD tolvaptan trials [PDF]

open access: yes
Autosomal dominant polycystic kidney disease (ADPKD) is the leading genetic cause of kidney disease [1]. Tolvaptan, a vasopressin V2-receptor antagonist, is the only disease-modifying therapy available with proven efficacy in slowing disease progression.
Mallett, Andrew J.   +13 more
core   +1 more source

Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease

open access: yesCanadian Journal of Kidney Health and Disease, 2017
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disorder worldwide. The disease is characterized by renal cysts and progressive renal failure due to progressive enlargement of cysts and renal fibrosis. An estimated
Steven Soroka   +9 more
doaj   +1 more source

SNX9 Inhibits Cell Proliferation and Cyst Development in Autosomal Dominant Polycystic Kidney Disease via Activation of the Hippo-YAP Signaling Pathway

open access: yesFrontiers in Cell and Developmental Biology, 2020
Autosomal dominant polycystic kidney disease (ADPKD) is a complex process, involving the alteration of multiple genes and signaling pathways, and the pathogenesis of ADPKD remains largely unknown.
Ai-Wen Shen   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy